118482-03-4

Usage

Uses

Used in Pharmaceutical Industry:
N-CYCLOPROPYLBENZENE-1,2-DIAMINE is used as an intermediate in the production of various pharmaceuticals for its ability to contribute to the development of medicinal compounds.
Used in Dye Industry:
In the dye industry, N-CYCLOPROPYLBENZENE-1,2-DIAMINE is utilized as an intermediate to produce a range of dyes, leveraging its chemical properties to create colorants for various applications.
Used in Polymer Industry:
N-CYCLOPROPYLBENZENE-1,2-DIAMINE is employed as a component in the synthesis of polymers, contributing to the development of materials with specific properties for diverse uses.
Used in Organic Synthesis:
As a building block in organic synthesis, N-CYCLOPROPYLBENZENE-1,2-DIAMINE is used for the creation of complex organic molecules, playing a crucial role in the formation of advanced chemical structures.

Upstream product

• 55432-23-0 cyclopropyl-(2-nitro-phenyl)-amine 
• 1493-27-2 ortho-nitrofluorobenzene 
• 88-73-3 2-Chloronitrobenzene 

Downstream Products

• 202859-73-2 1-cyclopropyl-1,3-dihydro-2H-benzimidazol-2-one 
• 118482-04-5 1-cyclopropyl-2-methylbenzimidazole 
• 1179813-58-1 methyl 8-(2-(cyclopropylamino)phenylamino)-8-oxooctanoate 
• 1024010-53-4 2-chloro-N-(2-(cyclopropylamino)phenyl)nicotinamide 

Relevant academic research and scientific papers

METALLOENZYME INHIBITOR COMPOUNDS

Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF

The present invention disclosed a class of pyrimidine or pyridine compounds, pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, preparation method therefor and pharmaceutical compositions and pharmaceutical uses thereof. The compounds can inhibit the variants of EGFR (Epidermis Growth Factor Receptor) proteinases, and therefore can inhibit the growth of a variety of tumor cells effectively. The compounds can be used to prepare antitumor drugs, used for the treatment, combined therapy or prevention of various different cancers. The compounds can overcome the drug resistance induced by the existing first-generation EGFR inhibitors such as gefitinib, erlotinib and so on. Particularly, the compounds can be used to prepare drugs for treating or preventing diseases, disturbances, disorders or conditions mediated by epidermis growth factor receptor variants (such as L858R activated mutants, Exon19 deletion activated mutants and T790M resistant mutants).

Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase

This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

QUINAZOLINE BASED RESPIRATORY SYNCYTIAL VIRUS INHIBITORS

Compounds of Formula (I), wherein R1, R2, R3, R4 and n are defined herein, are useful as inhibitors of RSV.

RESPIRATORY SYNCYTIAL VIRUS INHIBITORS

Compounds of Formula (I): wherein R1, R2 and R3 are defined herein, are useful as inhibitors of RSV.

Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents

A series of benzimidazole based HDAC inhibitors have been rationally designed, synthesized and screened. The SAR of this new chemotype is described. The lead compound, 11e, showed strong activity in several cellular assays and demonstrated in vivo efficacy in mouse xenograft pancreatic cancer models.

INHIBITORS OF HISTONE DEACETYLASE

Compounds which are histone deacetylase inhibitors and their use in treating various disorders, including Alzheimer's Disease.

Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators

Compounds of Formula I: wherein A, B, D, L, R1, R2, R3, R4, m, and n are as defined for Formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

QUINOXALINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES

The present invention relates to quinoxalinone derivatives of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as defined in claim 1, as insulin secretion stimulators. The invention also relates to the preparation and use of these quinoxalinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated. Other preferred compounds are compounds of general formula (I), wherein R1, R2, R3, R4, R5 and R6 can be optionally substituted by one or more groups selected from Z.

4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Potent and selective p70S6 kinase inhibitors

We report herein the design and synthesis of 4-(benzimidazol-2-yl)-1,2,5-oxadiazol-3-amine derivatives as inhibitors of p70S6 kinase. Screening hits containing the 4-(benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine scaffold were optimized for p70S6K potency and selectivity against related kinases. Structure-based design employing an active site homology model derived from PKA led to the preparation of benzimidazole 5-substituted compounds 26 and 27 as highly potent inhibitors (Ki 100-fold selectivity against PKA, ROCK and GSK3.